ACH-CANDESARTAN TABLET
국가: 캐나다
언어: 영어
출처: Health Canada
제품 특성 요약
(SPC)
12-04-2017
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
CANDESARTAN CILEXETIL
제공처:
ACCORD HEALTHCARE INC
ATC 코드:
C09CA06
INN (국제 이름):
CANDESARTAN
복용량:
8MG
약제 형태:
TABLET
구성:
CANDESARTAN CILEXETIL 8MG
관리 경로:
ORAL
패키지 단위:
30/100
처방전 유형:
Prescription
치료 영역:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
제품 요약:
Active ingredient group (AIG) number: 0135220002; AHFS:
승인 상태:
APPROVED
승인 날짜:
2012-02-02
제품 특성 요약
Page 1 of 38
PRODUCT MONOGRAPH
ACH-CANDESARTAN
Candesartan Cilexetil
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AIMIPENEM AND CILASTATIN FOR INJECTION T
1
Receptor Blocker
Accord Healthcare Inc.
3535 boul. St. Charles suite 704
Kirkland, QC, H9H 5B9
Canada
Date of Revision:
March 30, 2017
Submission Control Number: 203995
Page 2 of 38
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
..........................................................................................................
8
DRUG INTERACTIONS
........................................................................................................
14
DOSAGE AND ADMINISTRATION
....................................................................................
17
OVERDOSAGE
.......................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
................................................................ 20
STORAGE AND STABILITY
................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................ 23
PART II: SCIENTIFIC INFORMATION
................................................................................
24
PHARMACEUTICAL INFORMATION
..............................................................................
24
CLINICAL TRIALS
.......................................................................
전체 문서 읽기
